Loading
Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates.

Monopar's team is located in San Francisco, CA and Chicago, IL.

Innovative Drugs and Drug Combinations

Licensing, developing and commercializing transformative oncology therapeutics

Why Oncology?

Multiple factors drive our passion for oncology

Market Demand

The numbers behind our research define camsirubicin opportunities

Corporate Overview

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization. 

Our Research Pipeline

Monopar’s pipeline consists of Phase 1b-stage camsirubicin, a proprietary analog of doxorubicin for the treatment of advanced soft tissue sarcoma, engineered specifically to minimize toxic effects on the heart while retaining anticancer activity; Phase 1-stage MNPR-101 for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers.



Product Indications Preclinical Phase 1 Phase 2 Phase 3 Status

Camsirubicin

Advanced Soft Tissue Sarcoma

Preclinical complete

Phase 1 in progress

Phase 2 not started

Phase 3 not started

Phase 1b trial ongoing in the US

MNPR-101-Zr

Imaging Agent for RIT

Preclinical complete

Phase 1 in progress

Phase 2 not started

Phase 3 not started

Collaboration with NorthStar, Phase 1

MNPR-101 RIT

Advanced Solid Cancers

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Collaboration with NorthStar, late preclinical

MNPR-202

Advanced Solid Cancers

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Early preclinical
Email Alerts

Stay informed and receive company updates straight to your inbox